180 Life Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

180 Life Sciences şirketinin toplam hissedar öz sermayesi $3.7M ve toplam borcu $483.7K olup, bu da borç-öz sermaye oranını 13% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $10.5M ve $6.7M dir.

Anahtar bilgiler

13.0%

Borç/özkaynak oranı

US$483.72k

Borç

Faiz karşılama oranı	n/a
Nakit	US$194.92k
Eşitlik	US$3.73m
Toplam yükümlülükler	US$6.74m
Toplam varlıklar	US$10.47m

Son finansal sağlık güncellemeleri

Recent updates

180 Life Sciences to raise $6.5M in direct stock offering

Jul 18

180 Life Sciences: Looking At Inflammation With Cannabis (Podcast)

Sep 08

What Type Of Shareholders Make Up 180 Life Sciences Corp.'s (NASDAQ:ATNF) Share Registry?

Feb 17

SPAC biotech 180 Life Sciences to ring Nasdaq opening bell today

Nov 27

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ATNF 'nin kısa vadeli varlıkları ( $1.2M ) kısa vadeli yükümlülüklerini ( $6.4M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: ATNF şirketinin kısa vadeli varlıkları ( $1.2M ) uzun vadeli yükümlülüklerini ( $352.3K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ATNF 'nin net borç/öz sermaye oranı ( 7.7% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: ATNF şirketinin borç/öz sermaye oranı son 5 yılda 6.1% seviyesinden 13% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ATNF şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: ATNF un, serbest nakit akışı her yıl % 13.5 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

180 Life Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

180 Life Sciences Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule

180 Life Sciences Expects to Meet Nasdaq Minimum Shareholders Equity Requirement as of September 30, 2024

180 Life Sciences Grants an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

180 Life Sciences Corp. Provides Non-Compliance Update

180 Life Sciences Corp. Provides Non-Compliance Update

180 Life Sciences Corp. Receives Delist Determination Letter from Nasdaq

Recent updates

180 Life Sciences Corp., Annual General Meeting, Dec 27, 2024

180 Life Sciences Corp. Appoints Jay Goodman as Independent Member of the Board of Directors and as Member of It's Audit Committee, as Well as Positions on Other Committees

180 Life Sciences Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule

180 Life Sciences Expects to Meet Nasdaq Minimum Shareholders Equity Requirement as of September 30, 2024

180 Life Sciences Corp. Announces Chief Financial Officer Changes

180 Life Sciences Corp. Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake

180 Life Sciences Grants an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

180 Life Sciences Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

180 Life Sciences Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

180 Life Sciences Corp. Provides Non-Compliance Update

180 Life Sciences Corp. Provides Non-Compliance Update

New major risk - Financial position

180 Life Sciences Corp. Receives Delist Determination Letter from Nasdaq

180 Life Sciences Corp. Announces Chief Executive Officer Changes

180 Life Sciences Corp. Announces Board Resignations

180 Life Sciences Corp. Announces Resignation of Donald A. Mcgovern, as Member of the Board of Directors

Nasdaq Provides 180 Life Sciences Written Notice That It Complies with Terms of Prior Extension, Company Complies with Listing Rule 5635(d)(1)(A)

180 Life Sciences Receives a Letter from Nasdaq

High number of new directors

180 Life Sciences Corp. Receives Formal Written Scientific Response from the United Kingdom's Medicines and Healthcare Products Regulatory Agency

180 Life Sciences Receives Non-Compliance Notice From Nasdaq

180 Life Sciences Corp. Receives Non-Compliance Letter from Nasdaq

New minor risk - Share price stability

180 Life Sciences Announces an Agreement for A Clinical Pharmacology Study Testing A New Formulation of Cbd for Enhanced Oral Uptake

180 Life Sciences Corp. Provides Update on Regulatory Approval Process in the UK and US for Dupuytren's Disease Treatment

180 Life Sciences Corp., Annual General Meeting, Jul 06, 2023

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

180 Life Sciences Corp. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

180 Life Sciences Provides Update on Progress to Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture

No longer forecast to breakeven

Price target decreased to US$4.00

High number of new and inexperienced directors

180 Life Sciences Receives Non-Compliance Letter from Nasdaq

180 Life Sciences Corp. Announces the First Patient Has Been Randomized in the Clinical Trial to Evaluate Anti-Tumor Necrosis Factor (TNF) for Patients with Early-Stage, Pain Predominant Frozen Shoulder

180 Life Sciences Corp. has completed a Follow-on Equity Offering in the amount of $6.500001 million.

180 Life Sciences to raise $6.5M in direct stock offering

180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for Therapy That Could Prevent Progression of Early-Stage Dupuytren’s Disease

180 Life Sciences Corp. Announces Following Publication of Promising Data from A Phase 2B Dupuytren’S Trial

180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology

Price target decreased to US$5.00

High number of new and inexperienced directors

180 Life Sciences Corp., Annual General Meeting, Jun 14, 2022

180 Life Sciences Corp. Provides an Update on its Anticipated Preliminary Discussion

180 Life Sciences Corp. Forms Scientific Advisory Board

Lead Independent Director recently bought US$103k worth of stock

180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results

180 Life Sciences: Looking At Inflammation With Cannabis (Podcast)

180 Life Sciences Corp. announced that it has received $15 million in funding

180 Life Sciences Corp. announced that it expects to receive $15 million in funding

180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2)

180 Life Sciences Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

180 Life Sciences Corp. announced delayed 10-Q filing

180 Life Sciences Corp. announced delayed annual 10-K filing

180 Life Sciences Receives Extension Until June 30, 2021 to Regain Compliance from Nasdaq

180 Life Sciences Corp. announced that it expects to receive $11.6662 million in funding

What Type Of Shareholders Make Up 180 Life Sciences Corp.'s (NASDAQ:ATNF) Share Registry?

New 90-day high: US$6.72

180 Life Sciences Corp. Announces Management Changes

180 Life Sciences Corp. Appoints Ozan Pamir to Serve as the Interim Chief Financial Officer

SPAC biotech 180 Life Sciences to ring Nasdaq opening bell today

180 Life Sciences Corp. announced delayed 10-Q filing

180 Life Sciences Corp. Announces Management Changes

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin